Current Research Studies
A Phase 4 Observational Study of Clinical Outcomes in Real-World Practice Settings for Pediatric and Adult Patients with Classic Congenital Adrenal Hyperplasia (CAH) Following or During Participation in Phase 3 CRENESSITY® (crinecerfont) Trials
NBI-74788-CAH4025
What is the goal of the study?
The primary objective of this study is to evaluate the real-world impact of CRENESSITY® (crinecerfont) in patients with CAH, including its effects on clinical endpoints associated with the disease (e.g., androgen control) and those related to disease management (e.g., glucocorticoid use). The secondary objective of this study is to characterize patients’ treatment history and disease trajectory prior to CRENESSITY® (crinecerfont) initiation to provide clinical context for observed outcomes. Additional secondary objectives may arise as research interests develop. Any additional research objectives will be outlined in further detail in one or more SAP(s).
Who can participate in the study?
Please contact the study team listed below to learn more.